CLAIMS

1. A therapeutically effective amount of an antiviral agent comprising valacyclovir, acyclovir, famciclovir, pritelivir, tenofovir, ganciclovir, glycyrrhizic acid, sambucus nigra, or valganciclovir, or a salt, solvate or combination thereof for use in a method of pre- exposure prophylaxis against HSV infection in an HSV seronegative subject, in which the antiviral agent is orally administered to the subject prior to sexual contact with a partner who is seropositive for HSV.

2. An antiviral agent for use according to Claim 1, in which the therapeutically effective amount of the antiviral agent is from 5 mg to 2000 mg, preferably 500 mg to 2000 mg.

3. An antiviral agent for use according to Claim 1 or 2, in which a therapeutically effective amount of an additional antiviral agent is administered to the subject.

4. An antiviral agent for use according to Claim 3, in which the additional antiviral agent is an HIV antiviral agent, preferably in which the HIV antiviral agent comprises tenofovir, emtricitabine, lamivudine, efavirenz, raltegravir, dolutegravir, maravoric, rilpirivine, or a salt, solvate or combination thereof.

5. An antiviral agent for use according to any preceding claim, in which an effective amount of a contraceptive is further administered to the subject, preferably in which the contraceptive comprises levonorgestrel, estradiol, dosogestrel, ethinyl estradiol, norethindrone acetate, norgestimate, or a salt, solvate or combination thereof.

6. An antiviral agent for use according to Claim 5, in which the contraceptive is an emergency contraceptive if the antiviral agent is administered after physical contact with the partner who is seropositive for HSV, preferably in which the emergency contraceptive comprises levonorgestrel.

7. An HSV treatment kit comprising

(a) a therapeutically effective amount of a first antiviral agent comprising valacyclovir, acyclovir, famciclovir, pritelivir, tenofovir, ganciclovir, glycyrrhizic acid, sambucus nigra, or valganciclovir, or a salt, solvate or combination thereof;

(b) a delivery device for orally delivering the first antiviral agent to an HSV seronegative subject; and

(c) instructions comprising information on how to administer the first antiviral agent using the delivery device to prevent HSV infection in the HSV seronegative subject.

8. A kit according to Claim 7, in which the therapeutically effective amount of the first antiviral agent is an amount useful for the prevention of HSV infection in the HSV seronegative subject when administered to the HSV seronegative subject prior to exposure to HSV.

9. A kit according to Claim 7 or 8, further comprising one or more additional antiviral agents, preferably in which the one or more additional antiviral agents comprises an HSY antiviral agent, an HIV antiviral agent, or both HSY and HIV antiviral agents.

10. A kit according to Claim 9, in which the HIV antiviral agent comprises tenofovir, emtricitabine, lamivudine, efavirenz, raltegravir, dolutegravir, maravoric, rilpirivine, or a salt, solvate or combination thereof.

11. A kit according to any of Claims 7 to 10, further comprising an effective dose of a contraceptive, preferably in which the contraceptive comprises levonorgestrel, estradiol, dosogestrel, ethinyl estradiol, norethindrone acetate, norgestimate, or a salt, solvate or combination thereof.

CLAIMS

1. A therapeutically effective amount of an antiviral agent comprising valacyclovir, acyclovir, famciclovir, pritelivir, ganciclovir, glycyrrhizic acid, sambucus nigra, or valganciclovir, or a salt, solvate or combination thereof for use in a method of pre-exposure prophylaxis against HSV infection in an HSV seronegative subject, in which the antiviral agent is to be orally administered to the subject prior to sexual contact with a partner who is seropositive for HSV.

2. An antiviral agent for use according to Claim 1, in which the therapeutically effective amount of the antiviral agent is from 5 mg to 2000 mg.

3. An antiviral agent for use according to Claim 1 or 2, in which the therapeutically effective amount of the antiviral agent is from 500 mg to 2000 mg.

4. An antiviral agent for use according to Claim 1, 2 or 3, in which a therapeutically effective amount of an additional antiviral agent is to be administered to the subject.

5. An antiviral agent for use according to Claim 4, in which the additional antiviral agent is an HIV antiviral agent.

6. An antiviral agent for use according to Claim 5, in which the HIV antiviral agent comprises tenofovir, emtricitabine, lamivudine, efavirenz, raltegravir, dolutegravir, maravoric, rilpirivine, or a salt, solvate or combination thereof.

7. An antiviral agent for use according to any preceding claim, in which an effective amount of a contraceptive is further to be administered to the subject.

8. An antiviral agent for use according to Claim 7, in which the contraceptive comprises levonorgestrel, estradiol, dosogestrel, ethinyl estradiol, norethindrone acetate, norgestimate, or a salt, solvate or combination thereof.